Market Newsdesk

July 6, 2026 2:06 am

NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 6, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”), of the important August 11, 2026 lead plaintiff deadline.

So what: If you purchased Nano-X securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Nano-X class action, go to https://rosenlegal.com/cases/nano-x-imaging-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants overstated purported efficiency gains achieved in Nano-X’s operations, as well as the purported increased demand for its products; (2) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for Nano-X’s products; (3) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (4) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Nano-X class action, go to https://rosenlegal.com/cases/nano-x-imaging-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nnox-investors-have-opportunity-to-lead-nano-x-imaging-ltd-securities-fraud-lawsuit-302818054.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 6, 2026 2:03 am

Kosmos Energy Provides Operational Update

Strong operational and financial performance in first half 2026

DALLAS, July 06, 2026 (GLOBE NEWSWIRE) — Kosmos Energy (NYSE/LSE: KOS) (“Kosmos” or the “Company”) is pleased to provide the following update on activities across its portfolio:

In Ghana, the third well of the 2026 campaign, J76, was completed and came online in mid-June, two weeks later than initially planned. Initial production rates have been very strong with the new well, which benefits from the latest seismic and Kosmos’ reservoir modelling, contributing approximately 20,000 barrels of oil per day (bopd) to gross production. Jubilee production in the second quarter 2026 was approximately 72,000 bopd with an exit rate above 85,000 bopd.

The next well in the program, J77, has been completed and production is expected imminently. This well is expected to take gross Jubilee production to approximately 90,000 bopd. The final producer well (J50) is a completion of a previously drilled well and is expected online around the end of July. To complete this year’s drilling program, a water injector well is expected online around the end of the third quarter, which will prepare the northeastern area of Jubilee for the 2027/2028 drilling program. Two full Jubilee cargo liftings and one TEN lifting took place in the second quarter, in line with guidance. A third Jubilee cargo began lifting on the last day of the quarter and was completed on July 2.

In Mauritania and Senegal, the Greater Tortue Ahmeyim (GTA) LNG project continues to perform strongly with nine LNG cargos lifted in the second quarter, at the upper end of guidance. A condensate cargo was also lifted during the second quarter.

In the Gulf of America, post the sanction of Tiberius in March, the farm down continues to make good progress, with completion expected in the third quarter.

In Equatorial Guinea, the completion of the sale of the Ceiba and Okume assets to Panoro Energy took place on June 16, 2026. From this date until quarter end, no further production has been recognized from these assets, removing approximately 1,000 barrels of oil per day from second quarter production guidance. Full year guidance will be updated to reflect the disposal with the second quarter results in August.

On the finance side, net debt at the end of the second quarter fell to approximately $2.56 billion, a drop of over $400 million since year-end 2025, driven by proactive debt reduction initiatives as well as free cash flow. The company remains on track to deliver a reduction in net debt of around 20% year-on-year by the end of 2026. Liquidity at quarter end was in excess of $500 million and discussions with our bank group are expected to begin shortly to re-finance and extend the maturity of the reserve-based lending facility.

Andrew G. Inglis, Kosmos Energy’s chairman and chief executive officer said: “We continue to execute on the key priorities I outlined with our full year results in early March – growing production, reducing costs and paying down debt. Initial results from the 2026 Ghana drilling program, in particular J76, highlight the potential of Jubilee with high-impact wells, supported by both modern seismic and enhanced reservoir modelling. With strong operational and financial performance in the first half of the year, we remain well placed to deliver our targets for the year.”

About Kosmos Energy

Kosmos Energy is a leading deepwater exploration and production company focused on meeting the world’s growing demand for energy. We have diversified oil and gas production from assets offshore Ghana, Mauritania, Senegal and the Gulf of America. Additionally, in the proven basins where we operate, we are advancing high-quality development opportunities, which have come from our exploration success. Kosmos is listed on the NYSE and LSE and is traded under the ticker symbol KOS. As an ethical and transparent company, Kosmos is committed to doing things the right way. The Company’s Business Principles articulate our commitment to transparency, ethics, human rights, safety and the environment. Read more about this commitment in the Kosmos Sustainability Report. For additional information, visit www.kosmosenergy.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Kosmos expects, believes or anticipates will or may occur in the future are forward-looking statements. Kosmos’ estimates and forward-looking statements are mainly based on its current expectations and estimates of future events and trends, which affect or may affect its businesses and operations. Although Kosmos believes that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made in light of information currently available to Kosmos. When used in this press release, the words “anticipate,” “believe,” “intend,” “expect,” “plan,” “will” or other similar words are intended to identify forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Kosmos, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on such assumptions, risks and uncertainties is available in Kosmos’ Securities and Exchange Commission (“SEC”) filings. Kosmos undertakes no obligation and does not intend to update or correct these forward-looking statements to reflect events or circumstances occurring after the date of this press release, except as required by applicable law. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Investor Relations

Jamie Buckland
+44 (0) 203 954 2831
[email protected]

Media Relations

Thomas Golembeski
+1-214-445-9674
[email protected]

July 6, 2026 1:59 am

MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 6, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Microsoft Corporation (NASDAQ: MSFT) between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”), of the important August 11, 2026 lead plaintiff deadline.

So What: If you purchased Microsoft common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Microsoft class action, go to https://rosenlegal.com/cases/microsoft-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Microsoft’s Copilot family of products had experienced significant brand positioning, user experience, usage, data siloing, computational capacity, organizational, and interoperability problems; (2) Microsoft’s flagship proprietary AI model ranked well below competitors on a number of benchmark tests; (3) Microsoft needed to increase by billions of dollars its capital expenditures and divert graphics processing unit (“GPU”) and central processing unit (“CPU”) capacity away from fulfilling demand for its profitable Azure services in order to improve the competitive positioning of its critical Copilot family of products and increase its AI-related research and development (“R&D”); and (4) as a result, Microsoft had failed to convert a significant percentage of its commercial Microsoft 365 users to paid Copilot subscriptions and Microsoft’s Copilot offerings had lost market share to rival products, a trend that was increasing. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Microsoft class action, go to https://rosenlegal.com/cases/microsoft-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:https://www.prnewswire.com/news-releases/msft-investors-have-opportunity-to-lead-microsoft-corporation-securities-fraud-lawsuit-302818042.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 6, 2026 1:03 am

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Phase 1/2a trial of MP0712,
²¹²
Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027
Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing
²²⁵
Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectors
FIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026
New target nomination in H2 2026, with two INDs planned in 2027

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update across its pipeline of targeted alpha Radio-DARPin therapeutics (RDTs).

“Molecular Partners has made significant progress in the first months of 2026, with our DLL3 radiotherapy candidate MP0712 progressing through Phase 1 initiation and dosing of patients in the first cohort. In addition, we have shown impressive data highlighting the unique advantages of our DARPins as interchangeable, isotope-agnostic vectors for alpha-emitting payloads, enabling us to tailor radiopharmaceuticals to target and disease biology. We look forward to first clinical data on MP0712 and to progressing our next Radio-DARPin candidates to first-in-human imaging in the second half of the year,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.

Dosing of patients is ongoing in the first cohort of the US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479). MP0712, targeting the tumor-associated protein delta-like ligand 3 (DLL3) and carrying the therapeutic payload Lead-212 (²¹²Pb), is being developed for patients with small cell lung cancer and other neuroendocrine cancers, with strategic partner Orano Med. The Phase 1 study contains up to 4 dose levels (cohorts). Each patient will receive up to 4 doses of MP0712 within their assigned dose level. At present five centers are open and recruiting. Initial data from the MP0712 Phase 1/2a study are expected within the next months, with a more comprehensive dataset on safety and efficacy in 2027.

Based on his successful experience with MP0712 and on access to other isotopes, Dr. Mike Sathekge of the Nuclear Medicine Research Institute (NuMeRI) in South Africa has made a request for an early-access clinical program (under the legal framework for compassionate care in South Africa, Section 21 of the Medicines and Related Substances Act) with a DLL3-targeting Radio-DARPin, this time utilizing ¹⁷⁷Lu/²²⁵Ac as theranostics pair to image and treat patients, respectively (referred to as MP0714). Molecular Partners remains fully focused on the execution of the US Phase 1/2a study of MP0712 with ²¹²Pb. PanTera, a leading radioisotope producer, is among the suppliers of ²²⁵Ac for the use of MP0714 at NuMeRI. This work is enabled by the versatility of DARPins to interchange isotopes.

The Company’s ability to explore targets in an alpha isotope-agnostic manner is supported by preclinical data presented at the 3^rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China. The data show highly comparable biodistribution profiles of two Radio-DARPin candidates, each specific for a different tumor target, labeled with ¹⁷⁷Lu or ²⁰³Pb. Imaging with ¹⁷⁷Lu can be indicative of behavior with the therapeutic isotope ²²⁵Ac, and similarly with ²⁰³Pb for ²¹²Pb.

MP0726, the Company’s second Radio-DARPin candidate, targets mesothelin (MSLN), a tumor target overexpressed across several cancers with high unmet need such as ovarian cancer. Molecular Partners plans to advance MP0726 towards first-in-human imaging in H2 2026.

As part of its growing pipeline, the Company plans two INDs across its portfolio of targeted cancer therapeutics in 2027 and expects to nominate a new RDT target in the second half of this year.

About Radio-DARPins
Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners’ Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches, while preserving the advantages of the small protein format. Molecular Partners has established partnerships with industry leaders covering the full value chain for the development of its Radio-DARPin therapeutics, including a strategic collaboration with Orano Med – pioneer in the development of ²¹²Pb-based targeted alpha therapies (TAT), a non-exclusive development agreement with Eckert & Ziegler – global leader in radiopharmaceutical manufacturing, and a supply agreement with PanTera – a leading ²²⁵Ac radioisotope producer.

About DARPin Therapeutics

DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. Powered by twenty years of DARPin leadership, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:

Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
[email protected]
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
[email protected]
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

July 5, 2026 8:30 pm

HUBG Investors Have Opportunity to Lead Hub Group, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 5, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of purchasers of securities of Hub Group, Inc. (NASDAQ: HUBG) between April 28, 2023 and May 11, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026.

So What: If you purchased Hub Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Hub Group’s financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements—caused by the premature and incorrect recognition of certain transactions—concerning, inter alia, Hub Group’s operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth. In addition, Hub Group’s financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements—caused by the understatement of purchased transportation costs and accounts payable —concerning, inter alia, Hub Group’s operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:https://www.prnewswire.com/news-releases/hubg-investors-have-opportunity-to-lead-hub-group-inc-securities-fraud-lawsuit-302817350.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 5, 2026 7:47 pm

Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 5, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

So What: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis’ flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zoetis-deadline-zts-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-zoetis-inc-securities-fraud-lawsuit-302817281.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 5, 2026 7:19 pm

CHX Deadline: CHX Investors with Losses in Excess of $100K Have Opportunity to Lead ChampionX Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 5, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds sellers of common stock of ChampionX Corporation (NASDAQ: CHX) between February 29, 2024 and April 1, 2024 (the “Class Period”), of the important July 14, 2026 lead plaintiff deadline.

So what: If you sold ChampionX common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the ChampionX class action, go to https://rosenlegal.com/cases/championx-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period failed to disclose material information, which artificially deflated the price of ChampionX common stock. On February 29, 2024, ChampionX received an unsolicited non-public offer from Schlumberger Limited to purchase all the outstanding shares of ChampionX for $36.70 per share. On March 7, 2024, Schlumberger raised its offer to $37.80 per share. The lawsuit alleges that while these offers were on the table and unknown to the investing public, ChampionX was repurchasing its common stock at market prices significantly below the prices offered by Schlumberger. ChampionX had an obligation to disclose that it had received a formal acquisition offer from Schlumberger or abstain from purchasing ChampionX stock from unsuspecting investors. During the Class Period, ChampionX’s average stock price was $33.32 per share. On Tuesday, April 2, 2024, during pre-market hours, ChampionX disclosed the merger with Schlumberger. The merger eventually closed on July 16, 2025, with Schlumberger acquiring ChampionX for $40.58 per share.

To join the ChampionX class action, go to https://rosenlegal.com/cases/championx-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:https://www.prnewswire.com/news-releases/chx-deadline-chx-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-championx-corporation-securities-fraud-lawsuit-302817290.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 5, 2026 7:03 pm

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on FF’s Robotics Q3 Campaign, EAI Robotics Summer Camps and Insight Into FF’s Delivery, Service, and Operations Capabilities

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on FF’s Robotics Q3 Campaign, EAI Robotics Summer Camps and Insight Into FF’s Delivery, Service, and Operations Capabilities

Starting July 6, FF will launch its first three flagship demonstration robotics summer camps. FF will partner with two major public-school districts in Los Angeles — Lynwood Unified School District and El Segundo Unified School District, where FF’s headquarters is located — to host these EAI robotics summer camps.
FF recently signed a strategic cooperation MOU with El Segundo Unified School District, further expanding FF’s partnership footprint among public school districts.
Last week, FF took part in ISTE Live 2026 in Orlando, the largest education technology conference in North America, and was the only U.S.-based EAI robotics company at the event. FF used this opportunity to advance collaboration with K–12 schools, educational institutions, FF Par partners, developers, and ecosystem partners.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260705756356/en/

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on FF’s Robotics Q3 Campaign, EAI Robotics Summer Camps and Insight Into FF’s Delivery, Service, and Operations Capabilities

“Welcome to our weekly report issue 62. As July begins, FF officially kicked off the “FF Robotics Q3 Campaign”. For FF Robotics, the third quarter will be focused on strengthening our foundation. We will continue to leverage FF’s five unique values as a U.S.-based EAI robotics company and accelerate the implementation of our FF EAI Robot World device strategy, built around “one brain, multiple forms” and “multiple forms, multiple capabilities.” We will deepen our efforts across four major sector and ecosystem segments, with a strong focus on education and industrial applications — two frontier markets we are actively building — while continuing to grow in inspection & security and other existing markets. Our goal is to enable increasingly specialized and professionalized FF robots to create practical value and establish closed-loop commercial models more quickly across real-world scenarios.

Today, I would like to first share the key progress from the opening move on the Q3 sales front. Starting July 6, FF will launch its first three flagship demonstration robotics summer camps. We will partner with two major public-school districts in Los Angeles — Lynwood Unified School District and El Segundo Unified School District, where FF’s new Silicon Beach headquarters is located — to host these EAI robotics summer camps. At the same time, FF will officially launch its summer camp collaboration with Triple I, a U.S. full-service education institution, providing support and enablement across products, technology, curriculum content, and the broader education ecosystem.

In addition, following our collaboration with Lynwood Unified School District, FF recently signed a strategic cooperation MOU with El Segundo Unified School District, further expanding our partnership footprint among public school districts.

With the first three flagship summer camp partners now in place — two public school district partners and one private education partner — this partnership structure has three important implications.

First, it creates a cooperation model and set of standards that can be scaled across the U.S. This will help accelerate sales conversion for FF products, drive the rapid growth of the world’s first Three-in-One EAI robotics education ecosystem, and support FF’s goal of building the No. 1 brain and No. 1 foundational model for the global EAI robotics education ecosystem.

Second, for education institutions, FF provides a complete, ready-to-deploy EAI robotics education solution and curriculum Skills, helping public school districts and K-12 education institutions bring cutting-edge AI and Physical AI education to students with a lower barrier to entry and higher standards.

Third, from the family education perspective, the summer camps will give many American children and parents their first close-up, immersive experience with EAI robots. This will help children open the door to the world of Physical AI earlier and grow into masters and creators of the AI-native era.

The second point I want to share is key progress we made in the EAI robotics education ecosystem. After becoming the star of the show at Automate, FF once again became a standout highlight at ISTE Live 2026, North America’s largest education technology conference held from June 29 to July 1, as the only U.S.-based EAI robotics company at the event. This further validated that “Physical AI + education” is becoming an emerging trend in both school district procurement and family education. Through an EAI robotics education ecosystem serving both B2C family education and B2B education institutions, FF is accelerating its expansion into mainstream North American channels and turning its first-mover advantage in early delivery into a sustainable market-leading position.

During the event, FF’s industrial-grade mobile manipulator, Faber S, also made its debut. As the Faber sub-series with the longest arm reach and the most complete embodied intelligence data-collection toolchain, Faber S is designed for wide-area operations and embodied AI data collection. Its core use cases include machine tending, material handling, logistics, and other factory applications, while it can also support research and teaching, reception and guided services, and additional scenarios. It is a true industrial-grade EAI skilled craftsman.

On the product and technology side, FF’s open-source and open developer platform recently completed several interactive human-robot courseware mini-games, including a traffic-light game. These mini-games are now in final testing and will soon launch on the FF Robot Store. While these lightweight courseware games may appear simple, they are highly suitable for educational settings. They can help increase usage frequency while also enabling the platform to validate the full loop from application development, store listing, and distribution to user feedback. This lays a strong foundation for the future productization of Skills, Agents, and data.

Finally, I would like to talk about issues, reflections, and solutions. While demand and sales continue to exceed our expectations, shortcomings in our industrialization system capabilities have also become clear. The most immediate issue is that our delivery capacity has not yet kept pace with the speed of our sales ramp-up. Internally, outside the area surrounding our California headquarters, FF’s delivery, service, and operations capabilities in other states still need to be strengthened. This is the main bottleneck limiting faster delivery. Externally, as this is a brand-new market, mature industry standards and closed-loop systems have not yet been established. At this stage, the only path forward is to deliver, explore, learn, build capabilities, and evolve at the same time — turning challenges into opportunities.

Next, as part of the Q3 Campaign, we will continue to amplify our strengths and quickly close our capability gaps. Next week, we will share more about the Q3 Campaign plan and our execution priorities. See you next week!”

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a Three-in-One ecosystem of “Device, Data, EAI Brain & Open-Source and Open Platform,” FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding potential future legal actions against alleged illegal market manipulation or similar improper activities, and FF’s entry into the embodied AI robotics market and robotics deliveries and development, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to timely regain compliance with Nasdaq’s minimum bid requirement; the Company’s common stock will be suspended from trading on Nasdaq if it’s closing price is $0.10 or less for 10 consecutive trading days; the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; the willingness of convertible debt investors to fund the Company while it lacks sufficient share capital for conversions; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the Company’s reliance on a single OEM for most of its robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260705756356/en/

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Vehicle Technology EV/Electric Vehicles Hardware Robotics Alternative Vehicles/Fuels Technology Other Education Automotive Artificial Intelligence Primary/Secondary Education Automotive Manufacturing Manufacturing

MEDIA:

Photo

Logo

July 5, 2026 5:56 pm

CVLT Deadline: CVLT Investors with Losses in Excess of $100K Have Opportunity to Lead Commvault Systems, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 5, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

So what: If you purchased Commvault securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Commvault class action, go to https://rosenlegal.com/cases/commvault-systems-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details Of The Case: According to the lawsuit, defendants provided overwhelmingly positive statements while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Commvault’s ARR growth environment; pertinently, Commvault knew or recklessly disregarded that its ARR growth guidance failed to properly factor in crucial variables, such as the type of sale. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Commvault class action, go to https://rosenlegal.com/cases/commvault-systems-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cvlt-deadline-cvlt-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-commvault-systems-inc-securities-fraud-lawsuit-302817289.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 5, 2026 5:12 pm

LCID Deadline: LCID Investors with Losses in Excess of $100K Have Opportunity to Lead Lucid Group, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 5, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the “Class Period”), of the important July 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid’s business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:https://www.prnewswire.com/news-releases/lcid-deadline-lcid-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-lucid-group-inc-securities-fraud-lawsuit-302817288.html

SOURCE THE ROSEN LAW FIRM, P. A.